Sergliflozin etabonate

chembox new
ImageFile=Sergliflozin etabonate.svg
ImageSize=280
IUPACName=2- [(4-methoxyphenyl)methyl] phenyl 6-"O"-(ethoxycarbonyl)-β-D-glucopyranoside
OtherNames=
Section1=Chembox Identifiers
CASNo=408504-26-7
PubChem=9824918
SMILES=CCOC(=O)OCC1C(C(C(C(O1)OC2=CC=CC=C2CC3=CC=C(C=C3)OC)O)O)O
MeSHName=Sergliflozin
Section2=Chembox Properties
Formula=C₂₃H₂₈O₉
MolarMass=448.463 g/mol
Appearance=
Density=
MeltingPt=
BoilingPt=
Solubility=
Section3=Chembox Hazards
MainHazards=
FlashPt=
Autoignition=

Sergliflozin etabonate (INN/USAN, [cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 59 |journal = WHO Drug Information |volume = 22 |issue = 1 |year = 2008 |pages = 66 |url = http://whqlibdoc.who.int/druginfo/INN_2008_list59.pdf] [cite web |url=http://www.ama-assn.org/ama1/pub/upload/mm/365/sergliflozin_etabona.pdf |title=Statement on a nonproprietary name adopted by the USAN council: Sergliflozin etabonate |accessdate=2008-08-10 |date= |publisher=American Medical Association] codenamed GW869682X) is an investigational anti-diabetic drug being developed by GlaxoSmithKline. It is an inhibitor of SGLT2. [cite journal |author=Katsuno K, Fujimori Y, Takemura Y, "et al" |title=Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level |journal=J Pharmacol Exp Ther |volume=320 |issue=1 |pages=323–30 |year=2007 |month=January |pmid=17050778 |doi=10.1124/jpet.106.110296 |url=http://jpet.aspetjournals.org/cgi/content/full/320/1/323]

ee also

*Dapagliflozin
*Remogliflozin

References